Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer From Benign Prostate Hyperplasia

Pavel A. Markin, MS, PhD(c); Alex Brito, MS, PhD; Natalia Moskaleva, MS, PhD; Miguel Fodor, MD; Ekaterina V. Lartsova, MD; Yevgeny V. Shpot, MD, PhD; Yulia V. Lerner, MD; Vasily Y. Mikhajlov, MD, PhD; Natalia V. Potoldykova, MD; Dimitry V. Enikeev, MD, PhD; Alexey V. Lyundup, PhD; Svetlana A. Appolonova, MS, PhD


Lab Med. 2020;51(6):566-573. 

In This Article


Plasma sarcosine concentrations measured by GC-MS analysis had "good" and "very good" classification performance for distinguishing PIN and PCa, respectively, relative to noncancerous patients, suggesting that it may be a promising complementary biomarker when used together with PSA. Further research is needed to better assess if plasma sarcosine differentiates patients diagnosed with PCa with different Gleason scores.